Buy Full Version
"World Lymphoma Therapeutics Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

World Lymphoma Therapeutics Market - Opportunities and Forecasts, 2019-2026

Pharmaceuticals	LI_181448	Pages: NA	Jan 2020 \| 1369 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Lymphoma comprises of a diverse group of blood cancers with different causes and treatment pathways. It is mainly categorized into two forms i.e., Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). According to the American Cancer Society (ACS), NHL is one of the most frequently diagnosed cancer in the U.S. that represent 4% of all types of cancers.

The global lymphoma therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL therapeutics market is the major market among global lymphoma therapeutics market. The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth. Rising prevalence of lymphoma, increasing funding from different governments, growing awareness and accelerated approvals offered by the regulatory authorities are the other factors that would propel the market growth. On the other hand, premium pricing of drugs, limited reimbursement and looming resistance toward the approved therapies would curtail the market growth.

The patent cliffs of blockbuster drugs would offer lucrative opportunities for new entrants and existing companies. Conversely, the emergence of resistance toward established therapies would remain as a key challenge for the drug innovators.

The market is expected to register substantial growth in mid-term due to the various strategies adopted by the leading industry players. One of the key strategies adopted is co-promotion and commercialization. Recently, EMD Serono entered into an agreement with Pfizer to co-promote its anaplastic lymphoma kinase (ALK) inhibitor Xalkori in the U.S. market.

The report segments the lymphoma drugs market on the basis of cancer type, therapy type and geography. Based on cancer type, the market is segmented into Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). On the basis of therapy type, the market is segmented into targeted therapy, chemotherapy, immunotherapy and others. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche AG, Eli Lilly, Pfizer Inc., Bristol-Myers Squibb (BMS) and others are also provided in the report.

KEY MARKET BENEFITS:

The report provides an extensive analysis of the current and emerging market trends and dynamics in the global lymphoma drugs market
Extensive research is done for the market by therapy type, which elucidates the currently used chemotherapy and targeted therapy drugs, evolving role of immunotherapies and in-line extensions opted for existing drugs
The report covers the detailed quantitative analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
The study highlights the competitive landscape and a detailed value chain analysis helps in understanding the competitive environment across various geographies
A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
Competitive intelligence highlights the business practices followed by the leading market players across various geographies
Owing to an emerging pipeline in the lymphoma drugs market, clinical studies have also been taken into account to better understand the market potential and opportunities
The lymphoma drugs market scenario is comprehensively analyzed in accordance with the key regions

KEY MARKET SEGMENTS:

The global lymphoma drugs market segmentation is illustrated below:

Lymphoma Drugs Market By Cancer Type

Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)

Lymphoma Drugs Market By Therapy Type

Targeted Therapy
Approved drugs
Pipeline drugs
Chemotherapy
Approved drugs
Pipeline drugs
Immunotherapy
Others

Lymphoma Drugs Market By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- U.K.
- Germany
- France
- Rest of Europe
Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia Pacific
LAMEA
- Latin America
- Middle East & Africa

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. PATENT ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 LYMPHOMA THERAPEUTICS MARKET, BY TYPE

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HODGKIN LYMPHOMA
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Classic Hodgkin lymphoma
4.2.2.1.1. Market size and forecast
4.2.2.2. Nodular lymphocyte predominant Hodgkin lymphoma
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. NON-HODGKIN LYMPHOMA (NHL)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. B-cell lymphomas
4.3.2.1.1. Market size and forecast
4.3.2.2. T-cell lymphomas
4.3.2.2.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

CHAPTER 5 LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. CHEMOTHERAPY
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. TARGETED THERAPY
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. IMMUNOTHERAPY
5.4.1. Market size and forecast, by type
5.4.1.1. Immune checkpoint inhibitors
5.4.1.1.1. Market size and forecast
5.4.1.2. Chimeric antigen receptor (CAR) T-cell therapy
5.4.1.2.1. Market size and forecast
5.4.1.3. Monoclonal antibodies
5.4.1.3.1. Market size and forecast
5.4.2. Market size and forecast, by region
5.4.3. Market analysis, by country
5.5. RADIATION THERAPY
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. STEM CELL/BONE MARROW TRANSPLANTATION
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. SURGERY
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country

CHAPTER 6 LYMPHOMA THERAPEUTICS MARKET, BY END USER

6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. CLINICS
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. AMBULATORY SURGICAL CENTERS (ASCS)
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7 MARKET ANALYSIS, BY COUNTRYLYMPHOMA THERAPEUTICS MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America lymphoma therapeutics market, by country
7.2.2.1. U.S. lymphoma therapeutics market
7.2.2.1.1. U.S. market, by type
7.2.2.1.2. U.S. market, by treatment
7.2.2.1.3. U.S. market, by end user
7.2.2.2. Canada lymphoma therapeutics market
7.2.2.2.1. Canada market, by type
7.2.2.2.2. Canada market, by treatment
7.2.2.2.3. Canada market, by end user
7.2.2.3. Mexico lymphoma therapeutics market
7.2.2.3.1. Mexico market, by type
7.2.2.3.2. Mexico market, by treatment
7.2.2.3.3. Mexico market, by end user
7.2.3. North America lymphoma therapeutics market, by type
7.2.4. North America lymphoma therapeutics market, by treatment
7.2.5. North America lymphoma therapeutics market, by end user
7.3. EUROPE
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe lymphoma therapeutics market, by country
7.3.2.1. Germany lymphoma therapeutics market
7.3.2.1.1. Germany market, by type
7.3.2.1.2. Germany market, by treatment
7.3.2.1.3. Germany market, by end user
7.3.2.2. France lymphoma therapeutics market
7.3.2.2.1. France market, by type
7.3.2.2.2. France market, by treatment
7.3.2.2.3. France market, by end user
7.3.2.3. UK lymphoma therapeutics market
7.3.2.3.1. UK market, by type
7.3.2.3.2. UK market, by treatment
7.3.2.3.3. UK market, by end user
7.3.2.4. Italy lymphoma therapeutics market
7.3.2.4.1. Italy market, by type
7.3.2.4.2. Italy market, by treatment
7.3.2.4.3. Italy market, by end user
7.3.2.5. Spain lymphoma therapeutics market
7.3.2.5.1. Spain market, by type
7.3.2.5.2. Spain market, by treatment
7.3.2.5.3. Spain market, by end user
7.3.2.6. Rest of Europe lymphoma therapeutics market
7.3.2.6.1. Rest of Europe market, by type
7.3.2.6.2. Rest of Europe market, by treatment
7.3.2.6.3. Rest of Europe market, by end user
7.3.3. Europe lymphoma therapeutics market, by type
7.3.4. Europe lymphoma therapeutics market, by treatment
7.3.5. Europe lymphoma therapeutics market, by end user
7.4. ASIA-PACIFIC
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific lymphoma therapeutics market, by country
7.4.2.1. Japan lymphoma therapeutics market
7.4.2.1.1. Japan market, by type
7.4.2.1.2. Japan market, by treatment
7.4.2.1.3. Japan market, by end user
7.4.2.2. China lymphoma therapeutics market
7.4.2.2.1. China market, by type
7.4.2.2.2. China market, by treatment
7.4.2.2.3. China market, by end user
7.4.2.3. Australia lymphoma therapeutics market
7.4.2.3.1. Australia market, by type
7.4.2.3.2. Australia market, by treatment
7.4.2.3.3. Australia market, by end user
7.4.2.4. India lymphoma therapeutics market
7.4.2.4.1. India market, by type
7.4.2.4.2. India market, by treatment
7.4.2.4.3. India market, by end user
7.4.2.5. South Korea lymphoma therapeutics market
7.4.2.5.1. South Korea market, by type
7.4.2.5.2. South Korea market, by treatment
7.4.2.5.3. South Korea market, by end user
7.4.2.6. Rest of Asia-Pacific lymphoma therapeutics market
7.4.2.6.1. Rest of Asia-Pacific market, by type
7.4.2.6.2. Rest of Asia-Pacific market, by treatment
7.4.2.6.3. Rest of Asia-Pacific market, by end user
7.4.3. Asia-Pacific lymphoma therapeutics market, by type
7.4.4. Asia-Pacific lymphoma therapeutics market, by treatment
7.4.5. Asia-Pacific lymphoma therapeutics market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA lymphoma therapeutics market, by country
7.5.2.1. Brazil lymphoma therapeutics market
7.5.2.1.1. Brazil market, by type
7.5.2.1.2. Brazil market, by treatment
7.5.2.1.3. Brazil market, by end user
7.5.2.2. Saudi Arabia lymphoma therapeutics market
7.5.2.2.1. Saudi Arabia market, by type
7.5.2.2.2. Saudi Arabia market, by treatment
7.5.2.2.3. Saudi Arabia market, by end user
7.5.2.3. South Africa lymphoma therapeutics market
7.5.2.3.1. South Africa market, by type
7.5.2.3.2. South Africa market, by treatment
7.5.2.3.3. South Africa market, by end user
7.5.2.4. Rest of LAMEA lymphoma therapeutics market
7.5.2.4.1. Rest of LAMEA market, by type
7.5.2.4.2. Rest of LAMEA market, by treatment
7.5.2.4.3. Rest of LAMEA market, by end user
7.5.3. LAMEA lymphoma therapeutics market, by type
7.5.4. LAMEA lymphoma therapeutics market, by treatment
7.5.5. LAMEA lymphoma therapeutics market, by end user

CHAPTER 8 COMPANY PROFILES

8.1. F. HOFFMANN-LA ROCHE LTD
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. ELI LILLY AND CO.
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. PFIZER INC.
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. BRISTOL-MYERS SQUIBB CO.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. CEPHALON, INC.
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. CELGENE CORPORATION
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. GLAXOSMITHKLINE PLC
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. ACCREDO HEALTH GROUP INC.
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. BAXTER INTERNATIONAL INC.
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. BAYER AG
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com